Literature DB >> 20638818

Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer.

M Imano1, T Itoh, T Satou, Y Sogo, H Hirai, H Kato, A Yasuda, Y F Peng, M Shinkai, T Yasuda, H Imamoto, K Okuno, H Shiozaki, H Ohyanagi.   

Abstract

BACKGROUND: We performed short-term neoadjuvant chemotherapy (s-NAC) to examine whether anticancer drugs can change the proliferative ability of cancer cells in gastric cancer patients.
METHODS: Chemotherapy was performed for 72 h before gastrectomy in 63 gastric cancer patients. Patients were classed into four groups: Group F, 16 cases who received a single administration of 5-fluorouracil (5-FU); Group C, 15 cases who received a single administration of cis-diamminedichloroplatinum (CDDP; cisplatin); Group FC, 16 cases who received both 5-FU+CDDP; and a Control group, 16 cases who did not receive chemotherapy. We reviewed neoadjuvant biopsy tissue and gastric cancer tissue delivered by operation in these cases. The TUNEL method and immunohistochemistry with an anti-MIB-1 antibody were used to evaluate cellular apoptosis and proliferative ability, respectively. The apoptotic index (AI) and an MIB-1 index (MI) were also calculated.
RESULTS: There were no differences in AI or MI in biopsy tissue between the groups. The AI of gastric cancer tissue in Group FC was significantly higher than in the other groups (P < 0.01). The MI of Group FC was significantly lower than in the other groups (P < 0.05). In addition, after s-NAC operation there was a significant inhibition of proliferative potency and an induction of apoptosis in Group FC.
CONCLUSION: Combination of CDDP and 5-FU reduced proliferative potency and increased cellular apoptosis in gastric cancer cells.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638818     DOI: 10.1016/j.ejso.2010.06.012

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

Review 1.  Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis.

Authors:  Huiyu Luo; Liucheng Wu; Mingwei Huang; Qinwen Jin; Yuzhou Qin; Jiansi Chen
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

2.  COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Tom van den Ende; Frank A Abe Nijenhuis; Héctor G van den Boorn; Emil Ter Veer; Maarten C C M Hulshof; Suzanne S Gisbertz; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

Review 3.  Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials.

Authors:  A-Man Xu; Lei Huang; Wei Liu; Shuang Gao; Wen-Xiu Han; Zhi-Jian Wei
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 4.  Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?

Authors:  Rossella Reddavid; Silvia Sofia; Paolo Chiaro; Fabio Colli; Renza Trapani; Laura Esposito; Mario Solej; Maurizio Degiuli
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

5.  A Machine Learning Model for Predicting a Major Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer.

Authors:  Yonghe Chen; Kaikai Wei; Dan Liu; Jun Xiang; Gang Wang; Xiaochun Meng; Junsheng Peng
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

6.  Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery.

Authors:  Yonghe Chen; Dan Liu; Jian Xiao; Jun Xiang; Aihong Liu; Shi Chen; Junjie Liu; Xiansheng Hu; Junsheng Peng
Journal:  Gastroenterol Res Pract       Date:  2021-07-28       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.